PRAX, US74006W2070

BTIG raised its target for Praxis Precision Medicines stock to USD 826

Published on 10/14/2026 at 04:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BTIG maintained Buy for Praxis Precision Medicines stock on October 6, 2026. Q2 loss was USD 2.87 per share versus USD 3.67 consensus.

Analyst target and regulatory dates

BTIG lifted its Praxis Precision Medicines target from USD 810.00 to USD 826.00 on October 6, 2026.
Praxis reported a second-quarter 2026 loss of USD 2.87 per share against a USD 3.67 consensus loss.
The relutrigine PDUFA target is December 27, 2026, while estimated earnings are scheduled for November 4, 2026.

PRAX, US74006W2070, Illustration mit AI erstellt.

BTIG had raised its price target for Praxis Precision Medicines stock from USD 810.00 to USD 826.00 on October 6, 2026, while maintaining a Buy rating, according to MarketBeat. The move places regulatory execution and late-stage pipeline milestones at the center of the company story.

Three milestones shape the pipeline

Benzinga reported that Praxis had operating expenses of USD 96.90 million in the second quarter of 2026, including USD 69.40 million for research and development and USD 27.50 million for general and administrative costs. The company also held USD 1.40 billion in cash, cash equivalents and marketable securities at the quarter end.

On August 6, 2026, Praxis reported a second-quarter loss of USD 2.87 per share against a consensus loss of USD 3.67 per share, a USD 0.80 per-share improvement versus expectations, according to MarketBeat. The comparison matters because Praxis is funding commercial preparation before product approvals.

What does the target mean?

The USD 826.00 BTIG target reflects the analyst case for relutrigine and its potential use across developmental and epileptic encephalopathies. Markets Insider reported that the note cited a December 27, 2026 PDUFA target for relutrigine and Phase 3 EMERALD data expected in the fourth quarter of 2026.

Dates define the next test

Praxis announced inducement grants under Nasdaq Listing Rule 5635(c)(4) on October 2, 2026, according to its investor-relations page at Praxis Precision Medicines. The next regulatory marker is December 27, 2026, while StockAnalysis lists estimated earnings for November 4, 2026.

Regulatory execution remains central

Praxis is a biotechnology company developing central nervous system therapies through its Cerebrum and Solidus platforms. Its second-quarter cash balance of USD 1.40 billion and quarterly operating expenses of USD 96.90 million provide the numerical frame for the launch preparation described in the company update.